FENTANYL
Infusion Reaction
Providence Health & ServicesSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Infusion Reaction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Providence Health & Services | Phase 3 | BB |
Ketorolac Tromethamine Providence Health & Services | Phase 3 | B |
Benadryl Providence Health & Services | Phase 3 | B |
HYDROMORPHON Providence Health & Services | Phase 3 | B |
CETIRIZINE Providence Health & Services | Phase 3 | B |
Same molecule, other indications
FENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →